Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Coherus Bio (NQ: CHRS ) 1.800 +0.150 (+9.09%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,065,396 Open 1.660 Bid (Size) 1.730 (3) Ask (Size) 1.810 (3) Prev. Close 1.650 Today's Range 1.660 - 1.800 52wk Range 1.250 - 5.465 Shares Outstanding 114,725,740 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary June 30, 2024 Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... Via Talk Markets Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction June 27, 2024 – Transaction aligns with Coherus’ strategic focus on oncology – From Coherus BioSciences, Inc. Via GlobeNewswire Performance YTD -42.68% -42.68% 1 Month +9.76% +9.76% 3 Month -18.18% -18.18% 6 Month -23.40% -23.40% 1 Year -58.81% -58.81% More News Read More Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors June 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Recap: Coherus BioSciences Q4 Earnings March 13, 2024 Via Benzinga Earnings Preview For Coherus BioSciences March 12, 2024 Via Benzinga Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting April 08, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus Biosciences Stock Tumbled on Thursday March 14, 2024 Via The Motley Fool Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update March 13, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 March 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Completes Divestiture of Ophthalmology Franchise March 04, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Earnings Scheduled For March 13, 2024 March 13, 2024 Via Benzinga Coherus BioSciences Announces New Employment Inducement Grants February 23, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv February 21, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus BioSciences Stock Jumped Today February 06, 2024 Via The Motley Fool Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP February 05, 2024 From Coherus BioSciences, Inc. Via GlobeNewswire Why Coherus BioSciences Stock Is Sinking Today January 23, 2024 Via The Motley Fool Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
